MSP-1014 explained

Routes Of Administration:Oral
Class:Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Synonyms:MSP1014; MSP-1014.OX

MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.[1] [2] [3] [4] [5]

It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[6]

The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical. As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders. The chemical structure of MSP-1014 does not yet seem to have been disclosed. However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.[7]

Notes and References

  1. Web site: MSP 1014 . AdisInsight . 9 January 2024 . 29 October 2024.
  2. Web site: Delving into the Latest Updates on MSP-1014 with Synapse . Synapse . 26 October 2024 . 29 October 2024.
  3. Web site: Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder . BioSpace . 22 June 2023 . 29 October 2024 . MSP-1014 is a novel and patent-protected prodrug of psilocin, the active metabolite of psilocybin. MSP-1014 is anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. Preclinical studies comparing MSP-1014 to psilocybin suggest that the tolerability of MSP-1014 may be superior to psilocybin..
  4. Mindset Pharma . Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate . GlobeNewswire News Room . 14 November 2022 . 29 October 2024.
  5. Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912
  6. Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M . Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy . CNS Spectrums . 28. 4. 416–426 . July 2022 . 35811423 . 10.1017/S1092852922000888 . free .
  7. US . 2022/0289774 . Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders . Slassi A, Araujo J . Mindset Pharma Inc. . 7 March 2023 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MSP-1014".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.